ArticleJournal of economic entomology2022
Potential Management Options for the Invasive Moth Spodoptera frugiperda in Europe.
Article in Journal of economic entomology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- An Autolysis-Derived Trypsin Peptide Disrupts Digestive Homeostasis and Reduces Fitness inACS omega · 2026Article
- Biogenic Silica Nanoparticles EnhanceACS omega · 2026Article
- Insecticidal Activity of Trichilia hirta L. (Sapindales: Meliaceae) Extracts Against Spodoptera frugiperda (Lepidoptera: Noctuidae) Larvae and the Identification of Bioactive Compounds.Chemistry & biodiversity · 2026Article
- Molecular surveillance of resistance mutations in invasive populations of Spodoptera frugiperda in Europe, for evidence-based pest control.Pest management science · 2025Article
- Migration extent and potential economic impact of the fall armyworm in Europe.Scientific reports · 2025Article
- Article
- Government and farmer responses to the fall armyworm outbreak in mainland Southeast Asia.Frontiers in insect science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We here review and discuss management options that growers in Europe could take in response to the expected invasion of the fall armyworm, Spodoptera frugiperda (Lepidoptera: Noctuidae). The focus is put on maize but the information provided is also relevant for other crops potentially affected. A sound forecasting system for fall armyworm both on a regional as well as at local scale should be established to alert growers as early as possible. Whilst a number of cultural control methods are adopted by maize growers in different regions globally to fight fall armyworm, many of them may either not be highly effective, too laborious, or otherwise unfeasible within the mechanized crop production systems used in Europe. Potential is seen in the stimulation of natural enemies through conservation biocontrol approaches, e.g., the planting of flower strips or intermediate cover crops, reducing tillage intensity, and avoiding broad-spectrum insecticides. To manage fall armyworm infestations, several effective biologically-based products are available globally, and some in Europe, e.g., based on specific baculoviruses, certain Bacillus thuringiensis strains, few entomopathogenic nematodes, and a number of botanicals. These should be given priority to avoid a major influx of insecticides into the maize agro-ecosystem once the fall armyworm arrives and in case growers are not prepared. Plant protection companies, particularly biocontrol companies should act proactively in starting registration of ingredients and products against fall armyworm in Europe. European maize growers should be made aware, in time, of key features of this new invasive pest and appropriate control options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.